Excellgene
  • About
  • News & Blog
  • Services
    • Cell line development
    • HEKzeroT®
    • Biosimilars
    • Clonality assurance
    • AAV process development
    • Rapid Protein Production
    • Tox Material Production
    • cGMP Master Cell Banks
    • Downstream Process (DSP) Development
  • SARS-Cov-2 Proteins
    • All spike variants
    • Omicron Trimeric Spike
    • Delta Trimeric Spike
    • Beta Trimeric Spike
    • Alpha Trimeric Spike
    • Wuhan Trimeric Spike
    • RBD monomer
  • Technologies
  • Knowlege base
  • Contact
    • Get in touch
    • Careers
Select Page

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Recent Posts

  • A superior HEK cell line for AAV production
  • EXCELLGENE, Switzerland, and LOTTE BIOLOGICS, South Korea, Announce a Collaboration for Cell Line Development and Manufacturing of Biologics.
  • Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
  • Innovation in Vaccine Manufacturing
  • Developing a Variant-Proof SARS-CoV-2 Vaccine: a CEPI-funded ExcellGene Partnership with Bharat Biotech and the University of Sydney.

Recent Comments

No comments to show.
© ExcellGene SA., Route de l’Ile-aux-Bois 1A, 1870 Monthey, Switzerland.